PT-141 - Deus Medical

In June 2019 the FDA approved Bremelanotide (sold as Vyleesi) a receptor agonist used to address sexual desire, in premenopausal women with hypoactive sexual desire disorder (HSDD). Known for its approach and diverse results when compared to flibanserin; it operates by triggering neuropeptides linked to arousal. While the precise way it works is still under investigation bremelanotide attaches to melanocortin 1 and 4 receptors in the hypothalamus that play a role, in behavior and releases dopamine to boost desire. The medicine should be consumed at 45 minutes before engaging in activity; however its most effective timing is still being researched. Certain studies have shown that Bremelanotide may enhance desire and alleviate distress associated with concerns

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about PT-141 by Deus Medical, consult with your doctor or healthcare professional.